Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05464394
Other study ID # 2022-031
Secondary ID 2022-001384-27
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date September 1, 2022
Est. completion date September 1, 2025

Study information

Verified date July 2022
Source Franciscus Gasthuis
Contact Judith WH Hart, MD
Phone 010 - 461 6163
Email j.hart@franciscus.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The incidence of bleeding after metabolic surgery seems to increase. The administration of a drug (tranexamic acid) that can reduce bleeding could possibly also reduce bleeding after metabolic surgery. Objective: This study aims to determine whether administration of tranexamic acid before surgery can reduce postoperative bleeding in patients undergoing gastric bypass.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1524
Est. completion date September 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Primary metabolic procedure; - Gastric bypass: Roux-en-Y gastric bypass or One-anastomoses gastric bypass; - =18 years; - Good command of the Dutch or English language. Exclusion Criteria: - Patients unwilling to give informed consent; - Patients with a medical history of bleeding or VTE (defined as, pulmonary embolism (PE) or deep vein thrombosis (DVT)); - Patients who use anticoagulants; - Arterial bleeding or (iatrogenic) bleeding during the procedure coming from surrounding organs or vascular structures such as the liver or the spleen.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic Acid Injection [Cyklokapron]
A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
Sodium chloride 0.9%
100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Franciscus Gasthuis

Outcome

Type Measure Description Time frame Safety issue
Primary re-intervention rate To compare the re-intervention rate due to haemorrhage within 30 days postoperative, after peroperative administration of TXA versus placebo in patients receiving a RYGB or OAGB 30 days
Secondary the use of haemostatic staple devices measurement (yes/no). Peroperatively, only on active bleeding a heamostatic staple device will be used. If there is no bleeding no haemostatic staple device will be used. peroperatively
Secondary the use of fibrin sealant measurement (yes/no). Peroperatively, if the staple line is not actively bleeding but is oozing, fibrin sealant is used. If there is no oozing, fibrin sealant is not used. peroperatively
Secondary blood loss blood loss in ml during surgery peroperatively
Secondary haemoglobin decrease haemoglobin decrease postoperative 1 day
Secondary heart rate increase heart rate increase postoperative 1 day
Secondary number of suspicion on haemorrhage number of suspicion on haemorrhage for which extra haemoglobin monitoring 30 days
Secondary number of suspicion on haemorrhage for which extra haemoglobin monitoring number of suspicion on haemorrhage for which extra haemoglobin monitoring 30 days
Secondary VTE VTE postoperative 30 days
Secondary complications rates postoperative complications rates 30 days
Secondary length of hospital stay length of hospital stay 30 days
Secondary duration of primary surgery duration of primary surgery 1 day
See also
  Status Clinical Trial Phase
Completed NCT04058223 - Comparison of the Short-term Outcomes of Using DST and PPH Staplers in the Treatment of Grade III and IV Hemorrhoids
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Completed NCT04590898 - Peri-device Leakage Closure After LAAO
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Not yet recruiting NCT04537533 - Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss in Radical Cystectomy Operations Phase 4
Withdrawn NCT02851940 - Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids N/A
Completed NCT02722720 - Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral N/A
Recruiting NCT02279186 - Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section Phase 4
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Completed NCT02092415 - Assessment of Limb Perfusion During Junctional Tourniquet N/A
Completed NCT02980497 - Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study N/A
Completed NCT02245854 - Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps N/A
Not yet recruiting NCT01438736 - Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern? Phase 4
Completed NCT00515541 - Lovaza's Effect on the Activation of Platelets Phase 2
Completed NCT00143715 - Oral Vitamin K for Warfarin Associated Coagulopathy Phase 3
Terminated NCT03954314 - DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery Phase 3
Recruiting NCT05945680 - Tranexamic Acid in Breast Esthetic Surgery. Phase 4
Recruiting NCT03783182 - Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy Phase 4
Recruiting NCT03568890 - Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure Phase 4